Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Tofacitinib vs Methotrexate on Clinical and Molecular Disease Activity Markers in Joints and Lungs in Early Rheumatoid Arthritis (PULMORA) - A Randomized, Controlled, Open-label, Assessor-blinded, Phase IV Trial

NCT04311567 is registered in ClinicalTrials.gov with Vastra Gotaland Region as lead sponsor.

NCT NCT04311567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04311567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Tofacitinib vs Methotrexate on Clinical and Molecular Disease Activity Markers in Joints and Lungs in Early Rheumatoid Arthritis (PULMORA) - A Randomized, Controlled, Open-label, Assessor-blinded, Phase IV Trial
Lead sponsor
Vastra Gotaland Region
Phase
Phase 4
Overall status
Terminated
Start date
November 7, 2020
Completion date
March 26, 2024
Enrollment
3 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ild, interstitial lung disease due to systemic disease (disorder), ra, rheumatoid arthritis